检索结果-内蒙古大学图书馆

Generalized anxiety disorder versus panic disorder: Participation in controlled efficacy trials

COMPREHENSIVE PSYCHIATRY 2000年第4期41卷 253-258页

作者： Mavissakalian, MR Zamar, N Case Western Reserve Univ Dept Psychiat Cleveland OH 44106 USA Louis Stokes VAMC Cleveland OH USA

Seventy-one patients with panic disorder (PD) and 46 patients with generalized anxiety disorder (GAD) were studied in relation to their behavior before, during, and after participation in two contemporaneous and procedurally similar double-blind drug efficacy trials. The two groups were administered a battery of assessments aimed at comparing them on the nature and intensity of various symptom domains, social and work-related disability, personality, life events, and previous treatments. The results yielded few significant differences that were not due to definitional factors, most notably a more prevalent history of depression and treatment for depression in the GAD group and a higher rate of pharmacological treatment in the PD group. On the other hand, the two groups behaved in a comparable way in the screening, experimental, and postexperimental phases of the trials. The findings are in support of more similarities than differences between the groups. In addition, the comparable behavior of the two groups throughout the three phases of the trial suggests that differential pretreatment attrition and compliance with placebo-controlled trials may not present major confounding problems in comparative treatment effectiveness studies between GAD and PD diagnostic groups. Copyright (C) 2000 by W.B. Saunders Company.

关键词：阿普唑仑/治疗应用抗焦虑药/治疗应用焦虑症/诊断焦虑症/药物疗法咔啉类/治疗应用双盲法惊恐病/诊断惊恐病/药物疗法人格障碍/诊断个性量表疾病严重程度指数治疗结果成年人女(雌)性人类男(雄)性

来源：评论

学校读者我要写书评

暂无评论

Alosetron, a 5-HT₃ receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

引用

ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2000年第6期14卷 775-782页

作者： Houghton, LA Foster, JM Whorwell, PJ Univ S Manchester Hosp Dept Med Manchester M20 2LR Lancs England

Background: Alosetron is a potent and selective 5-HT3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non-constipated irritable bowel syndrome. Aim: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double-blind, placebo-controlled with a two-way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio-opaque markers;small bowel transit was determined from rise in breath hydrogen after a meal;and colonic transit and segmental transit were evaluated from abdominal X-ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients (P=0.128), which was confirmed in controls (P=0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non-constipated irritable bowel syndrome.

关键词：咔啉类/药理学咔啉类/治疗应用结肠/药物作用结肠/生理学结肠疾病功能性/药物疗法结肠疾病功能性/病理学交叉研究双盲法胃肠通过试验/药物作用小肠/药物作用小肠/生理学血清素拮抗药/药理学血清素拮抗药/治疗应用成年人女(雌)性人类男(雄)性中年人

来源：评论

学校读者我要写书评

暂无评论

New therapies for functional bowel diseases.

引用

Current gastroenterology reports 2000年第5期2卷 355-363页

作者： Coulie, B. Camilleri, M. GI Unit Mayo Clinic 200 First Street SW Rochester 55905 MN United States

During recent years, a greater understanding of the pathophysiology of functional bowel disease, and a surge of interest in this challenge among pharmacologists, basic scientists, and clinical investigators, have led to novel insights and promising therapies. The evidence to support current therapies in nonculcer dyspepsia and irritable bowel syndrome (IBS) is reviewed, and some of the novel therapeutic approaches on the threshold of clinical application are described.

关键词：咔啉类/治疗应用结肠疾病功能性/病理生理学结肠疾病功能性/治疗消化不良/病理生理学消化不良/治疗胃肠病用药/治疗应用心理疗法人类

来源：评论

学校读者我要写书评

暂无评论

Linezolid, Alosetron, Levetiracetam.

引用

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2000年第16期57卷 1480-1484页

来源：评论

学校读者我要写书评

暂无评论

Alosetron approved for treatment of irritable bowel syndrome

引用

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 2000年第6期57卷 519-519页

作者： [Anonymous]

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：